DTIL

Precision BioSciences Inc

Add to Watchlist

Advanced Chart

4.570

-0.24(-4.990%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.800

Open

4.570

VWAP

4.63

Vol

86.76K

Mkt Cap

50.67M

Low

4.500

Amount

401.98K

EV/EBITDA(TTM)

Total Shares

6.93M

-1.55M

EV/OCF(TTM)

P/S(TTM)

0.74

Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

5.40M

+746.39%

-2.240

-0.44%

5.37M

+831.71%

-2.205

-147.22%

Estimates Revision

The market is revising No Change the revenue expectations for Precision BioSciences, Inc. (DTIL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -11.78%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-11.78%

In Past 3 Month

3 Analyst Rating

651.20% Upside

Wall Street analysts forecast DTIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DTIL is 34.33 USD with a low forecast of 13.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

651.20% Upside

Current: 4.570

Low

13.00

Averages

34.33

High

60.00

651.20% Upside

Current: 4.570

Low

13.00

Averages

34.33

High

60.00

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$60

2025-03-28

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$60

2025-03-28

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$60

2025-03-19

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$60

2025-03-19

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$60

2025-02-19

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$60

2025-02-19

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$60

2025-01-10

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$60

2025-01-10

Reiterates

Strong Buy

Reason

BMO Capital

Kostas Biliouris

Hold

Buy

Upgrades

$34

2025-01-10

Reason

BMO Capital

Kostas Biliouris

Price Target

$34

2025-01-10

Upgrades

Hold

Buy

Reason

BMO Capital upgraded Precision BioSciences to Outperform from Market Perform with an unchanged price target of $34 alter iECURE announced clinical data in ornithine transcarbamylase using Precision's in vivo gene editor. The data appear "very promising," providing early clinical validation for Arcus, the analyst tells investors in a research note. As such, BMO sees a 65% probability for Precisions in vivo hepatitis B virus program to deliver acceptable safety and strong efficacy, driving 100%-200% upside in the shares. It believes Precision's risk/reward is favorable at current share levels.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$60

2024-08-22

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$60

2024-08-22

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Precision BioSciences Inc (DTIL.O) is -0.58, compared to its 5-year average forward P/E of -2.66. For a more detailed relative valuation and DCF analysis to assess Precision BioSciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.66

Current PE

-0.58

Overvalued PE

1.41

Undervalued PE

-6.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.83

Current EV/EBITDA

-0.14

Overvalued EV/EBITDA

3.69

Undervalued EV/EBITDA

-5.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

7.29

Current PS

3.15

Overvalued PS

14.86

Undervalued PS

-0.28

Financials

Annual

Quarterly

FY2025Q1

YoY :

-99.84%

29.00K

Total Revenue

FY2025Q1

YoY :

+428.11%

-22.11M

Operating Profit

FY2025Q1

YoY :

-339.46%

-20.57M

Net Income after Tax

FY2025Q1

YoY :

-230.00%

-2.21

EPS - Diluted

FY2025Q1

YoY :

+1.57%

-19.37M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

-9.39%

-115.40

FCF Margin - %

FY2025Q1

YoY :

-145296.13%

-70.91K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

63.2K

USD

3-6

Months

7.5K

USD

6-9

Months

264.1K

USD

0-12

Months

29.5K

USD

Bought

0-3

28.1K

USD

Months

3-6

47.1K

USD

Months

6-9

61.0K

USD

Months

0-12

20.3K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

63.2K

USD

3-6

Months

7.5K

USD

6-9

Months

264.1K

USD

0-12

Months

29.5K

USD

Bought

0-3

28.1K

USD

Months

3-6

47.1K

USD

Months

6-9

61.0K

USD

Months

0-12

20.3K

USD

Months

DTIL News & Events

Events Timeline

2025-08-06 (ET)

2025-08-06

09:24:53

Precision BioSciences reports safety, efficacy data for ELIMINATE-B trial cohort

2025-07-23 (ET)

2025-07-23

07:30:27

Precision BioSciences granted Orphan Drug Designation for PBGENE-DMD

2025-07-17 (ET)

2025-07-17

15:00:31

Precision BioSciences Duchenne muscular dystrophy treatment gets orphan status

News

9.0

08-06Newsfilter

PinnedPrecision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

9.5

08-04Newsfilter

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

9.0

07-23NASDAQ.COM

Precision BioSciences: FDA Grants Orphan Drug Designation For PBGENE-DMD